Quarterly report pursuant to Section 13 or 15(d)

Collaboration Agreements, Licenses and Other Research and Development Agreements (Details Narrative)

v3.21.1
Collaboration Agreements, Licenses and Other Research and Development Agreements (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Dec. 12, 2019
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Nov. 19, 2020
Dec. 13, 2019
Entity Listings [Line Items]            
Research and development expenses   $ 3,241,432 $ 4,086,883      
Revenue   33,333      
Cystic Fibrosis Foundation [Member]            
Entity Listings [Line Items]            
Deferred liability   153,000        
Research and development expenses   424        
Genentech [Member]            
Entity Listings [Line Items]            
Revenue   $ 33,000        
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]            
Entity Listings [Line Items]            
Therapeutics development award         $ 4,200,000  
Proceeds from award       $ 484,249    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Prepaid Expenses and Other Current Assets [Member]            
Entity Listings [Line Items]            
Related receivable       650,000    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Accrued Expense And Other Current Liabilities [Member]            
Entity Listings [Line Items]            
Deferred liability       $ 577,000    
Genentech Feasibility Study Agreement [Member] | Genentech [Member]            
Entity Listings [Line Items]            
Agreement description Genentech shall pay the Company a total of $100 thousand for developing oral formulations of three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement.          
Deferred revenue           $ 100,000